Cantuzumab provides a monoclonal antibody targeting the CanAg tumor-associated antigen specifically for cancer and antibody research. It recognizes a carbohydrate epitope associated with the mucin MUC1, which is expressed in several epithelial cancers and specifically supports studies of tumor antigen recognition, antibody-mediated targeting, and antibody-drug conjugate (ADC) development.
Key Features and Benefits
- CanAg-Targeting Antibody: Recognizes the CanAg tumor-associated carbohydrate antigen specifically found on certain epithelial cancer cells.
- Monoclonal Antibody Design: Provides a targeted antibody platform specifically for investigating antigen recognition and tumor-specific binding.
- MUC1-Associated Antigen Recognition: Supports investigation of CanAg carbohydrate epitopes associated with the MUC1 glycoprotein.
- Tumor Antigen Targeting: Enables studies of antibody binding to CanAg-expressing cancer cells.
- ADC Development Platform: Provides the antibody component used in the development of CanAg-directed ADCs, including Cantuzumab Ravtansine.
- Antibody Internalization Research: Supports investigation of antibody binding, cellular uptake, and antigen-mediated internalization.
- Cancer Biomarker Research: Useful for studying CanAg expression and its potential role specifically in identifying relevant tumor cell populations.
Applications
- Colorectal Cancer Research: Supports investigation of CanAg expression and antibody targeting in colorectal cancer models.
- Pancreatic Cancer Research: Useful for studying CanAg-associated antigen expression in relevant pancreatic cancer models.
- Gastric Cancer Research: Supports evaluation of CanAg-targeting strategies in gastric cancer models.
- Epithelial Cancer Research: Useful for investigating CanAg expression and antibody recognition across epithelial tumor models.
- Tumor Antigen Research: Supports studies of tumor-associated carbohydrate antigens and MUC1-associated epitopes.
- ADC Research: Provides an antibody platform for investigating CanAg-directed payload delivery and conjugation strategies.
- Antibody Binding Assays: Useful for evaluating antigen recognition, binding specificity, and antibody-cell interactions.
- Cellular Internalization Studies: Supports investigation of antibody uptake and intracellular trafficking in CanAg-expressing cells.
- Comparative Antibody Research: Useful for comparing tumor-associated antigen targeting and monoclonal antibody recognition strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Cantuzumab provides a CanAg-targeting monoclonal antibody for investigating tumor-associated carbohydrate antigens and antibody-mediated cancer cell recognition and specifically supports colorectal, pancreatic, gastric, and epithelial cancer research, as well as ADC development.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
